Beigene Ltd (BGNE) stock has fallen 1.72% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With BGNE Stock Today?
Beigene Ltd (BGNE) stock has risen 2.68% while the S&P 500 is unchanged 0% as of 2:59 PM on Tuesday, May 26. BGNE is up $4.27 from the previous closing price of $159.12 on volume of 216,682 shares. Over the past year the S&P 500 is higher by 5.46% while BGNE is up 32.72%. BGNE lost -$17.64 per share in the over the last 12 months.
To screen for more stocks like Beigene Ltd click here.
More About Beigene Ltd
BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.
